FULC vs. DYN, VERA, SRPT, APGE, NTLA, HROW, AUPH, IMCR, EWTX, and TWST
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Dyne Therapeutics (DYN), Vera Therapeutics (VERA), Sarepta Therapeutics (SRPT), Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA), Harrow (HROW), Aurinia Pharmaceuticals (AUPH), Immunocore (IMCR), Edgewise Therapeutics (EWTX), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.
Fulcrum Therapeutics vs. Its Competitors
Dyne Therapeutics (NASDAQ:DYN) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.
Dyne Therapeutics currently has a consensus price target of $34.07, indicating a potential upside of 160.85%. Fulcrum Therapeutics has a consensus price target of $9.60, indicating a potential upside of 4.12%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Fulcrum Therapeutics.
Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500.
96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Fulcrum Therapeutics' return on equity of -31.05% beat Dyne Therapeutics' return on equity.
In the previous week, Dyne Therapeutics had 7 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 9 mentions for Dyne Therapeutics and 2 mentions for Fulcrum Therapeutics. Dyne Therapeutics' average media sentiment score of 0.56 beat Fulcrum Therapeutics' score of 0.10 indicating that Dyne Therapeutics is being referred to more favorably in the media.
Fulcrum Therapeutics has higher revenue and earnings than Dyne Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Dyne Therapeutics beats Fulcrum Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FULC) was last updated on 10/5/2025 by MarketBeat.com Staff
